Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/109507
Title: Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases
Authors: Santiago, Ana R. 
Baptista, Filipa I. 
Santos, Paulo 
Cristovão, Gonçalo 
Ambrósio, A. Francisco 
Cunha, Rodrigo A. 
Gomes, Catarina A. 
Issue Date: 2014
Publisher: Hindawi
Project: SFRH/BPD/86830/2012 
SFRH/BPD/63013/2009 
PTDC/BIM-MEC/0913/2012 
PEst-C/SAU/LA0001/2013 
PEst-C/SAU/UI3282/2011 
metadata.degois.publication.title: Mediators of Inflammation
metadata.degois.publication.volume: 2014
Abstract: Neuroinflammation mediated by microglial cells in the brain has been commonly associated with neurodegenerative diseases. Whether this microglia-mediated neuroinflammation is cause or consequence of neurodegeneration is still a matter of controversy. However, it is unequivocal that chronic neuroinflammation plays a role in disease progression and halting that process represents a potential therapeutic strategy. The neuromodulator adenosine emerges as a promising targeting candidate based on its ability to regulate microglial proliferation, chemotaxis, and reactivity through the activation of its G protein coupled A2A receptor (A2AR). This is in striking agreement with the ability of A2AR blockade to control several brain diseases. Retinal degenerative diseases have been also associated with microglia-mediated neuroinflammation, but the role of A2AR has been scarcely explored. This review aims to compare inflammatory features of Parkinson's and Alzheimer's diseases with glaucoma and diabetic retinopathy, discussing the therapeutic potential of A2AR in these degenerative conditions.
URI: https://hdl.handle.net/10316/109507
ISSN: 0962-9351
1466-1861
DOI: 10.1155/2014/465694
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais

Show full item record

Page view(s)

138
checked on Oct 30, 2024

Download(s)

43
checked on Oct 30, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons